CYCC: Summary for Cyclacel Pharmaceuticals, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Tuesday, November 24, 2009, 4:28am EST - Canadian Markets open in 5 hours and 2 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Cyclacel Pharmaceuticals, Inc. (CYCC)

On Nov 23: 0.80 USD 0.00 (0.00%)

MORE ON CYCC

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Cyclacel Pharmaceuticals, Inc. (NGM:CYCC) Delayed quote data

Last Trade:	0.80 USD
Trade Time:	Nov 23
Change:	0.00 (0.00%)
Prev Close:	0.80
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	2.00

Day's Range:	N/A - N/A
52wk Range:	0.26 - 1.66
Volume:	0
Avg Vol (3m):	204,132
Market Cap:	19.55M
P/E (ttm):	N/A
EPS (ttm):	-1.10
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add CYCC to Portfolio

Download Data

HEADLINES

•	NYSSA Presents 13th Annual Biotech and Specialty Pharmaceuticals Conference
	Business Wire (Fri, Nov 20)

•	CYCLACEL PHARMACEUTICALS, INC. Financials
	EDGAR Online Financials (Wed, Nov 18)

•	[$$] Biotech Stock Mailbag: Cardium Therapeutics
	at RealMoney by TheStreet.com (Fri, Nov 13)

•	CYCLACEL PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
	EDGAR Online (Thu, Nov 12)

•	New Star Analyst Rankings for Cyclacel Pharmaceuticals, Inc.
	StarMine (Wed, Nov 4)

•	CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
	EDGAR Online (Tue, Nov 3)

•	Q3 2009 Cyclacel Pharmaceuticals, Inc. Earnings Release - Time Not Supplied
	CCBN (Tue, Nov 3)

•	CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule
	EDGAR Online (Fri, Oct 30)

•	Coverage initiated on Cyclacel Pharma by Merriman
	Briefing.com (Wed, Oct 28)

•	CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Material Modification to Rights of Security Holders
	EDGAR Online (Tue, Oct 20)

More Headlines for CYCC...

ANALYST

EPS Est (next year) (Dec-09) :	-0.89
EPS Est (in 2 years) (Dec-10) :	-0.75
Avg Rec (current)*:	1.5
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders.

Full Company Profile

Add to Portfolio

Email to a Friend

•